Effect of ultralow doses of antibodies to S-100 protein in animals with impaired cognitive function and disturbed emotional and neurological status under conditions of experimental Alzheimer disease.
Course administration of ultralow doses of antibodies to S-100 protein restores cognitive functions and neurological status, improves emotional state, and reduces anxiety in animals with modeled Alzheimer disease based on cholinergic system deficiency caused by subchronic treatment with scopolamine.
Voronina
T A
TA
Materia Medica Holding Research-and-Production Company, Moscow.
Belopol'skaya
M V
MV
Kheyfets
I A
IA
Dugina
Yu L
YL
Sergeeva
S A
SA
Epshtein
O I
OI
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D000906:Antibodies / Q000276:immunology* / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy; D001362:Avoidance Learning / Q000187:drug effects; D003071:Cognition / Q000187:drug effects*; D003072:Cognition Disorders / Q000188:drug therapy; D008297:Male; D009483:Neuropsychological Tests; D051381:Rats; D009418:S100 Proteins / Q000276:immunology*; D012601:Scopolamine / Q000627:therapeutic use
D000906:Antibodies; D009418:S100 Proteins; D012601:Scopolamine